...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis
【24h】

Efficacy and Safety of Cilostazol Therapy in Ischemic Stroke: A Meta-analysis

机译：西洛他唑治疗缺血性卒中的疗效和安全性的荟萃分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Antiplatelet therapy is recommended for patients who have experienced ischemic stroke. We performed a meta-analysis to compare the efficacy and safety of cilostazol with other antiplatelet therapies in patients with ischemic stroke. Methods: PubMed, EMBASE, MEDLINE, and the Cochrane Library were searched for randomized controlled trials published in English from May 1999 to May 2013. Clinical outcomes were compared by pooled and meta-regression analyses. Results: Nine studies involving 6328 patients satisfied our inclusion criteria. Stroke recurrence (including hemorrhagic and ischemic) with cilostazol use was 5.3% (157) versus 8.3% (248) in control group (risk ratio .63 [.52-.76], 95% confidence interval [CI]). Poststroke intracranial hemorrhage was .5% (16) with cilostazol versus 1.6% (46) in control group (risk ratio .36 [.21-.63], 95% CI). Poststroke extracranial bleeding complications occurred in 2.4% (66) of the patients taking cilostazol versus 3.9% (108) in control group (risk ratio .62 [.46-.83], 95% CI). No significant difference in cerebrovascular events (nonfatal stroke, intracranial hemorrhage, and transient ischemic attack) was found between the cilostazol group (8.2%, 246) versus control group (12.0%, 360; risk ratio .71 [.50-1.01], 95% CI). In addition, the cilostazol therapy brought about a nonsignificant reduction of cardiac adverse events (heart failure, myocardial infarction, and angina pectoris) comparing with control groups, with 3.8% (99) of the cilostazol group versus 4.7% (123) of control group (risk ratio, .81 [.62-1.04], 95% CI). Conclusions: Cilostazol, alone or in combination with aspirin, significantly reduces stroke recurrence, poststroke intracranial hemorrhage, and extracranial bleeding in patients with a prior ischemic stroke as compared with other antiplatelet therapies.
机译：背景：对于患有缺血性中风的患者，建议使用抗血小板治疗。我们进行了一项荟萃分析，比较西洛他唑与其他抗血小板疗法在缺血性中风患者中的疗效和安全性。方法：检索1999年5月至2013年5月以PubMed，EMBASE，MEDLINE和Cochrane图书馆进行的英语随机对照试验。对临床结局进行汇总和荟萃分析比较。结果：涉及6328名患者的9项研究符合我们的纳入标准。服用西洛他唑的中风复发率（包括出血性和缺血性）为5.3％（157），而对照组为8.3％（248）（风险比.63 [.52-.76]，置信区间[CI]为95％）。西洛他唑组卒中后颅内出血为0.5％（16），而对照组为1.6％（46）（风险比0.36 [.21-.63]，95％CI）。服用西洛他唑的患者卒中后颅外出血并发症发生率为2.4％（66），而对照组为3.9％（108）（风险比.62 [.46-.83]，95％CI）。西洛他唑组（8.2％，246）与对照组（12.0％，360）之间的脑血管事件（非致命性中风，颅内出血和短暂性脑缺血发作）无显着差异，风险比.71 [.50-1.01]， 95％CI）。此外，与对照组相比，西洛他唑治疗可显着减少心脏不良事件（心力衰竭，心肌梗塞和心绞痛），西洛他唑组为3.8％（99），而对照组为4.7％（123） （风险比，.81 [.62-1.04]，95％CI）。结论：与其他抗血小板治疗相比，西洛他唑单独或与阿司匹林联用可显着降低先前有缺血性中风的患者的中风复发，中风后颅内出血和颅外出血。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号